| Open Document File Size: 24,67 KBShare Result on Facebook
City TRIANGLE PARK / / Company Green Cross Corporation / BioCryst Pharmaceuticals BioCryst Pharmaceuticals / Shionogi & Co. Ltd. / BioCryst Pharmaceuticals Inc. / / Continent North America / Europe / / Country United States / India / / Currency USD / / Event FDA Phase / Earnings Announcement / Conference Call / / Facility American College of Rheumatology / / IndustryTerm treatment of hepatitis C / pharmaceuticals / manufacturing costs / peramivir active pharmaceutical ingredient / / MedicalCondition higher BCX4208 gout / cancer / hematological malignancies / kidney stones / large and expanding gout / gout / hereditary angioedema / diseases / co-morbid diseases / infectious diseases / approved and experimental gout / Phase 2b gout / influenza / inflammatory / / Organization American College / Department of Health and Human Services / / Person Jon P. Stonehouse / Patients With Gout / / / Position President and Chief Executive Officer / / Product allopurinol / Outlook / BCX4208 / / ProvinceOrState North Carolina / / Technology API / drug design / / URL www.biocryst.com / /
SocialTag |
BioCryst Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2011 Financial Results RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial r